Use the hyperlinks, where available to access additional clinical trial information.
Investigating the safety and efficacy of NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer, NEO-IMPACT.
Australasian Gastro-Intestinal Trials Group (AGITG)
Eligible participants will receive 6 treatment cycles every 2 weeks of combined immuno-chemotherapy (durvalumab with modified FOLFIRINOX). mFOLFIRINOX will be administered as a day patient in hospital, given via intravenous infusion (IV) on day 1 of each cycle. One of the chemotherapy drugs (5-FU) will be given as a continuous infusion over 46 hours via portable pump, so participants will return to hospital on day 3 to have this pump disconnected. Durvalumab will be given via IV on Day 1 of each second cycle. At the end of the 6 treatment cycles, participants will be assessed for their suitability for surgery. After surgery, all participants will then receive an additional 6 treatment cycles of chemotherapy (mFOLFIRINOX) alone.